C. Emes

Human monoclonal antibodies to the V3 loop of HIV-1 gp120 mediate variable and distinct effects on binding and viral neutralization by a human monoclonal antibody to the CD4 binding site.

S. Zolla-Pazner, L. Cavacini, M. Posner, 1993, Journal of acquired immune deficiency syndromes.

Effect of antibody valency on interaction with cell-surface expressed HIV-1 and viral neutralization.

L. Cavacini, M. Posner, J. Power, 1994, Journal of immunology.

Loss of serum antibodies to a conformational epitope of HIV-1/gp120 identified by a human monoclonal antibody is associated with disease progression.

L. Cavacini, K. Mayer, M. Posner, 1993, Journal of acquired immune deficiency syndromes.

Plasma pharmacokinetics and biological activity of a human immunodeficiency virus type 1 neutralizing human monoclonal antibody, F105, in cynomolgus monkeys.

L. Cavacini, M. Posner, J. Power, 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120.

L. Cavacini, M. Posner, R. Byrn, 1993, Journal of acquired immune deficiency syndromes.

Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41.

D. Montefiori, L. Cavacini, G. Lewis, 1998, AIDS research and human retroviruses.

A human anti-HIV autoantibody enhances EBV transformation and HIV infection.

D. Montefiori, D. Scadden, L. Cavacini, 1999, Clinical immunology.

Influence of heavy chain constant regions on antigen binding and HIV-1 neutralization by a human monoclonal antibody.

D. Montefiori, L. Cavacini, M. Posner, 1995, Journal of Immunology.